Stockscreener 앱 받기
19.57
1.91%
0.2086
전일 마감가:
$19.36
열려 있는:
$19.21
하루 거래량:
175.52K
Relative Volume:
1.33
시가총액:
$493.59M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.90%
1개월 성능:
+21.79%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$19.21
$20.34
1주일 범위
$16.32
$20.34
52주 변동 폭
$13.36
$20.34
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
명칭
Lb Pharmaceuticals Inc
전화
917-450-6581
주소
575 MADISON AVENUE, NEW YORK
LBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
19.51 | 487.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.27 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.81 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.23 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
902.23 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.61 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 개시 | Leerink Partners | Outperform |
| 2025-10-06 | 개시 | Piper Sandler | Overweight |
| 2025-10-06 | 개시 | Stifel | Buy |
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event | LBRX SEC FilingForm 8-K - Stock Titan
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer - Investing.com Nigeria
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals names Kaya Pai Panandiker as CCO - The Pharma Letter
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer By Investing.com - Investing.com South Africa
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - The Manila Times
LB Pharmaceuticals, Inc Announces Appointment of Kaya Pai Panandiker as Chief Commercial Officer - MarketScreener
LB Pharmaceuticals - Nasdaq
LB Pharmaceuticals Reports Strong Q3 and Strategic Progress - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot - theheraldreview.com
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference - The Manila Times
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 - Investing.com Nigeria
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 By Investing.com - Investing.com South Africa
LBRX: IPO raised $327.8M; LB-102 advances with strong data; Q3 net loss narrows to $3.6M - TradingView
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates - The Manila Times
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
LB Pharmaceuticals, Inc. (LBRX) Stock News Today - TipRanks
LB Pharmaceuticals Inc Rings the Closing Bell - Nasdaq
LB Pharmaceuticals Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement - Bloomberg.com
LB Pharmaceuticals Inc (LBRX) Recent Insider Transactions - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Latest Press Releases & Corporate News - Yahoo
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo! Finance Australia
Anna Eramo Net Worth (2025) - GuruFocus
Rebecca Luse Net Worth (2025) - GuruFocus
Lb Pharmaceuticals Inc (LBRX) 재무 분석
Lb Pharmaceuticals Inc (LBRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Lb Pharmaceuticals Inc 주식 (LBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
0.77%
0.84%
자본화:
|
볼륨(24시간):